4%), and acne vulgaris (2% vs
PhanJChangPIssaDTurnerRDodgeJWestanmoAet al
No delegated assessments, no automated protocols a physician directs your care at every stage
To view or add a comment, sign in Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial To view or add a comment, sign in Retatrutide continues to redefine the future of obesity treatment
Any consideration of combined use should only occur under specialist supervision (endocrinologist or metabolic physician) within a formal clinical trial or with robust multidisciplinary oversight
Most notably, after a median follow-up of 104 weeks, significantly fewer patients in the tirzepatide group than in the placebo group experienced worsening HF events or died from cardiovascular causes (36 patients [9.9%] vs